Collins Stewart upgrades Encysive Pharmaceuticals (ENCY) to Buy
More News related to ENCY
- Following Today's Kosan (KOSN) Buyout, Investors Look for Next Biotech Deal
- Notable Mergers and Acquisitions of the Day 4/15 (DAL/NWA, PFE/ENCY, MSFT)
- Pfizer (PFE) Completes Tender Offer for Shares of Encysive Pharmaceuticals (ENCY)
- Mergers and Acquisitions of the Day 4/8 (PFE/ENCY, MCF, PMFG)
- Pfizer (PFE) Subsidiary Extends Tender Offer for Shares of Encysive (ENCY)
More News related to Upgrades
- Davenport Upgrades Heinz (HNZ) to Buy
- First Analysis Upgrades Advisory Board Company (ABCO) to Overweight
- Jefferies & Co Upgrades Energy XXI (EXXI) to Hold
- Morgan Stanley Upgrades Iowa Telecom (IWA) to Equalweight
- Fox-Pitt Upgrades Eaton Vance (EV) to Outperform
Collins Stewart upgrades Encysive Pharmaceuticals Inc. (Nasdaq: ENCY) from Market Perform to Buy with a $3 price target.
The firm said, "We recently attended the 4th World Symposium on Pulmonary Hypertension where we
were, admittedly, surprised by the seeming positivity of European physician sentiment on Thelin."
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
